Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction
These findings support the established safety profile of dapagliflozin. The patient characteristics in the EVOLUTION-HF study closely resemble those in the DAPA-HF randomized trial. The observed treatment patterns indicate an optimization in guideline-directed medical therapy.
Authors
- Ana Batista (ORCID: https://orcid.org/0000-0001-5393-2256)
- Otília Simões
- José Silva‐Cardoso (ORCID: https://orcid.org/0000-0002-9774-9864)
- Marisa Pardal (ORCID: https://orcid.org/0000-0001-7068-3132)
- Mário Almeida (ORCID: https://orcid.org/0009-0004-5599-2067)
- Filipa Bernardo (ORCID: https://orcid.org/0000-0001-8245-0520)
- Fátima Franco
- Aurora Andrade (ORCID: https://orcid.org/0000-0002-2327-0893)
- Ana Oliveira Soares
- Sara Diogo Gonçalves (ORCID: https://orcid.org/0000-0002-8287-1357)
- Ana Teresa Timóteo (ORCID: https://orcid.org/0000-0001-6061-9663)
- Margarida Lopes
Institutions
- Hospitais da Universidade de Coimbra (PT)
- Hospital de São João (PT)
- Hospital Padre Américo (PT)
- Hospital de São José (PT)
- Hospital Prof. Dr. Fernando Fonseca (PT)
- Unidade Local de Saúde de Trás-os-Montes e Alto Douro (PT)
- Centro Hospitalar do Tâmega e Sousa (PT)
- Hospital de São Bernardo (PT)
- Hospital de Santa Marta (PT)
- Hospital Garcia de Orta (PT)
- AstraZeneca (Portugal) (PT)
- Universidade Nova de Lisboa (PT)
Publication Details
- Journal
- Revista Portuguesa de Cardiologia
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1016/j.repc.2025.08.007
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29